Wooridul Huebrain (KOSE:A118000) - Share price, News & Analysis

A118000 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	1/6
Financial Health	4/6
Dividends	0/6

A118000 Stock Overview

Wooridul Huebrain Limited engages in the medical, life and health, pharmaceutical, and storage businesses.

Rewards

PE ratio (10x) is below the KR market (14x)

Risk Analysis

Shareholders have been substantially diluted in the past year

Large one-off items impacting financial results

Profit margins (52.7%) are lower than last year

Does not have a meaningful market cap (₩98B)

Wooridul Huebrain Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Wooridul Huebrain
Historical stock prices
Current Share Price	₩1,155.00
52 Week High	₩2,325.00
52 Week Low	₩1,065.00
Beta	1.74
1 Month Change	-12.50%
3 Month Change	-13.81%
1 Year Change	-40.31%
3 Year Change	-49.56%
5 Year Change	-63.39%
Change since IPO	-87.71%

Recent News & Updates

Mar 22

There Are Some Holes In Wooridul Huebrain's (KRX:118000) Solid Earnings Release

Following the release of a positive earnings report recently, Wooridul Huebrain Limited's ( KRX:118000 ) stock...

Shareholder Returns

	A118000	KR Healthcare	KR Market
7D	2.2%	7.5%	1.6%
1Y	-40.3%	-39.9%	-14.2%

Return vs Industry: A118000 matched the KR Healthcare industry which returned -39.9% over the past year.

Return vs Market: A118000 underperformed the KR Market which returned -14.2% over the past year.

Price Volatility

Is A118000's price volatile compared to industry and market?
A118000 volatility
A118000 Average Weekly Movement	4.5%
Healthcare Industry Average Movement	5.8%
Market Average Movement	5.5%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: A118000 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: A118000's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2009	32	Soo-Kyung Kim	https://www.wooridulls.co.kr

Wooridul Huebrain Limited engages in the medical, life and health, pharmaceutical, and storage businesses. It sells medical equipment and appliances, health equipment, medicines, and computer servers. Wooridul Huebrain Limited was formerly known as Wooridul Life Sciences Limited and changed its name to Wooridul Huebrain Limited in April 2014.

Wooridul Huebrain Fundamentals Summary

How do Wooridul Huebrain's earnings and revenue compare to its market cap?
A118000 fundamental statistics
Market Cap	₩97.83b
Earnings (TTM)	₩9.82b
Revenue (TTM)	₩18.61b

10.0x

P/E Ratio

5.3x

P/S Ratio

Is A118000 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A118000 income statement (TTM)
Revenue	₩18.61b
Cost of Revenue	₩13.55b
Gross Profit	₩5.06b
Other Expenses	-₩4.75b
Earnings	₩9.82b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	115.89
Gross Margin	27.20%
Net Profit Margin	52.74%
Debt/Equity Ratio	24.8%

How did A118000 perform over the long term?

See historical performance and comparison

Valuation

Is Wooridul Huebrain undervalued compared to its fair value and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

9.97x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A118000's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A118000's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: A118000 is good value based on its PE Ratio (10x) compared to the Asian Healthcare industry average (17.4x).

PE vs Market: A118000 is good value based on its PE Ratio (10x) compared to the KR market (14x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A118000's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A118000 is good value based on its PB Ratio (0.8x) compared to the KR Healthcare industry average (2.3x).

Future Growth

How is Wooridul Huebrain forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

16.6%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wooridul Huebrain has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Wooridul Huebrain performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

56.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A118000 has a large one-off gain of ₩10.1B impacting its December 31 2021 financial results.

Growing Profit Margin: A118000's current net profit margins (52.7%) are lower than last year .

Past Earnings Growth Analysis

Earnings Trend: A118000 has become profitable over the past 5 years, growing earnings by 56.5% per year.

Accelerating Growth: A118000's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A118000 had negative earnings growth (-21%) over the past year, making it difficult to compare to the Healthcare industry average (33.2%).

Return on Equity

High ROE: A118000's Return on Equity (8.3%) is considered low.

Financial Health

How is Wooridul Huebrain's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: A118000's short term assets (₩80.4B) exceed its short term liabilities (₩53.3B).

Long Term Liabilities: A118000's short term assets (₩80.4B) exceed its long term liabilities (₩3.6B).

Debt to Equity History and Analysis

Debt Level: A118000 has more cash than its total debt.

Reducing Debt: A118000's debt to equity ratio has reduced from 64.8% to 24.8% over the past 5 years.

Debt Coverage: A118000's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if A118000's interest payments on its debt are well covered by EBIT.

Balance Sheet

Dividend

What is Wooridul Huebrain current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A118000's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A118000's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A118000's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A118000's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A118000 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Soo-Kyung Kim (72 yo)

no data

Tenure

Ms. Soo-Kyung Kim served as Chief Executive officer of Wooridul Pharmaceutical Limited (formerly known as Wooridul Life Sciences Ltd). Ms. Soo-Kyung Kim served as Co-Chief Executive Officer of Sudo Pharmac...

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 68.1%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/23 00:00
End of Day Share Price	2022/05/23 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31